Trial Profile
A Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Patients With Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 14 Nov 2023 Planned End Date changed from 30 Nov 2024 to 30 Nov 2025.
- 14 Nov 2023 Planned primary completion date changed from 30 Nov 2024 to 30 Nov 2025.
- 14 Mar 2023 Planned End Date changed from 30 Nov 2022 to 30 Nov 2024.